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risk thresholds (FNRTs) for primary prophylaxis with
CSFs.
OBJECTIVES: To determine the impact of CPMs on
FNRT estimates with the CSFs.
METHODS: Cost-minimization models based on stan-
dard decision theory were generated, incorporating 1)
probabilities and resource utilization from randomized
clinical trials and 2) unit cost information from local in-
stitutional sources. Sensitivity analyses were performed,
varying resource use, costs, and test performance charac-
teristics. FNRTs were derived at which cost equivalence
was reached in each model. The test performance of pos-
sible CPMs was assessed utilizing the likelihood ratio
(LR) for discriminating high-risk patients with probabil-
ity (prob[HR]).
RESULTS: Baseline cost-minimization models were
equated with CPMs with a LR  1.0. The FNRT for CSF
use decreases as hospitalization length of stay (LOS) or
cost/day increase. Any CPM associated with a LR
1
generates lower FNRTs than under baseline conditions.
Test efficiency of the CPMs improves with increasing
LR
, with optimal performance observed between 2.0
and 4.0. In balanced CPMs with LR
  3.0, FNRTs are
reached for costs/day of $1000, $1500, and $2000 at
0.21, 0.16, and 0.13 respectively. In unbalanced CPMs,
FNRTs are 10% at prob(HR)  0.4, 0.3, 0.2, and 0.1
at costs/day of $1700, $1000, $600, and $300, respec-
tively. 
CONCLUSIONS: Efficient CPMs to identify high-risk pa-
tients should be able to further reduce costs and FNRTs
for CSF use based on cost-minimization.
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OBJECTIVE: To evaluate the QoL of Ig-NHL patients
enrolled in a trial comparing the efficacy and safety of F
and CVP.
METHODS: The EORTC-QLQ-C30 (v1) questionnaire
was completed by all French- and English-literate patients
at baseline, during treatment, and after treatment. QoL
was expressed as a global health status (QL) and five
functional scores (FS); physical, emotional, social (SF), cog-
nitive (CF) and role (RF), for which high values indicate
better QoL. It was also expressed as eight symptom/single
item (SSI) scores: fatigue, nausea, and vomiting (NV),
pain, dyspnea (DY), insomnia, appetite loss, constipation
(CO), diarrhea (DI), and financial difficulties (FI) for
which lower values mean better QoL.
RESULTS: Of the 91 patients recruited (F  47, CVP 
44), 84 completed the questionnaire at baseline, 74 dur-
ing treatment, and 41 after treatment. All FS were high at
baseline (70–90) and varied from 1 to 12 points during
the study. All FS improved during treatment except CF
and QL in the F group, which remained unchanged; and
RF and SF in the CVP group, which deteriorated. The dif-
ference between groups reached statistical significance for
SF (p  0.0076) but not for RF (p  0.4597). All SSI
scores were low (10 to 40) and varied only slightly during
the trial. Most scores improved except DY and CO in the
F group and NV, CO, DI, and FI in the CVP group. 
CONCLUSIONS: QoL was high in these patients. The
higher incidence of nausea, vomiting, and alopecia ob-
served in the CVP group may explain the difference ob-
served for SF, and, to a lesser extent, RF.
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OBJECTIVE: The objective of this study was to deter-
mine the relationship between profile-based cancer-spe-
cific quality of life dimension scores, and EuroQol-5D
scores in a breast cancer surgery sample.
METHODS: Seventy-five breast cancer surgery patients
participated in the study. The patients completed the Func-
tional Living Index-Cancer (FLIC), the Functional Assess-
ment of Cancer Therapy-General Version (FACT-G), and
the EuroQol-5D (EQ-5D) at the same visit, and the order
of instruments was randomized. Scores on both the EQ-5D
classification system, as well as on the thermometer, were
obtained, and both scores were related to dimension scores
on the FLIC and the FACT-G. Information on the age of
the patient, the cancer stage, and the number of comorbid-
ities was obtained through chart review.
RESULTS: The mean age of patients was 60 (SD  10.7).
The majority of patients (96%) were diagnosed with ei-
ther stage I or stage II breast cancer. Over 90% of pa-
tients had up to three comorbid conditions, with hyperten-
sion being the most frequent. Mean scores on the EQ-5D
classification system and the thermometer were 87.4
(SD  13.6), and 86.6 (SD  12.6), respectively. Ceiling
effects were observed on the classification system as well
as the thermometer. Both linear and double log regres-
sion results showed that quality of life dimension scores
were significantly related to scores in both the EQ-5D
classification systems and the thermometer. FLIC dimen-
sion scores made statistically significant contributions to
the EQ-5D classification score, but not to the score ob-
tained on the thermometer. FACT-G dimension scores
did not contribute significantly to either the EQ-5D clas-
sification score or to the thermometer score.
CONCLUSION: The results of this study show that can-
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cer-specific quality of life dimension scores are signifi-
cantly related to EuroQol-5D scores.
CARDIOVASCULAR DISEASE
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OBJECTIVE: In an era of cost-conscientiousness and
budgetary restraints, the cost-effectiveness of lipid modu-
lator agents must be considered. The study objective was
to evaluate the cost-effectiveness ratio of lipid modulator
agents, based on the agent’s effects on total cholesterol/
HDL-cholesterol ratio (TC/HDL-c) and on the cost of ac-
quisition.
METHODS: The choice of TC/HDL-c for the efficacy
criterion was dictated by the overwhelming evidence that
it is the most predictive parameter in assessing CHD risk
when compared to other lipid/lipoprotein levels or ratios.
Also, the evidence supporting the crucial role played by
HDL is demonstrated in several studies, among which are
the Framingham Study, LRC-CPPT, MRFIT, and PRO-
CAM. The cost of acquisition of each medication was ob-
tained from the Quebec Provincial Formulary (Liste de
Medicament—July 1996). The meta-analysis of each dose
of each medication’s effects on TC/HDL was based on a
search generating 456 publications, from which 124 met
the appropriate criteria. 
RESULTS: From these publications, on average, the pop-
ulation is 50.5 years old, with 62.5% males; the baseline
TC/HDL is 7.3. The various doses of each medication
were ranked into three categories of efficacy based on the
percent decrease of the TC/HDL ratio: less than 20%,
20–30%, and greater than 30%.
CONCLUSION: In the most effective category, the medi-
cations which showed the best efficacy to cost ratio were
fluvastatin 60 mg (20% decrease per $ per day) and mi-
cronized fenofibrate 200 mg (19% decrease per $ per
day), and then simvastatin 20 mg (15% decrease per $
per day).
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In a previous analysis, based on the West of Scotland
Coronary Prevention Study (WOSCOPS), pravastatin
was demonstrated to lower the risk of cardiovascular dis-
ease (CVD) in hypercholesterolemic men, at an economic
efficiency that is not prohibitive overall from the perspec-
tive of the National Health Service in the UK. For these
results to provide guidance to those who set policy in
other jurisdictions, they must account for differences
among healthcare systems.
OBJECTIVE: The applicability of these findings to the
Belgian setting was investigated by integrating the
WOSCOPS results and Belgian epidemiological, resource
use, and cost data.
METHODS: The Belgian Interuniversity Research on
Nutrition and Health data were used to evaluate the
baseline risk factor distribution and to partially validate
the CVD exponential regression model derived from
WOSCOPS. The rates at which subjects move for the first
time from health to CVD were calculated, assuming the
relative efficacy for pravastatin observed in WOSCOPS.
The number of such transitions avoided was valued in
terms of cost savings to the Belgian healthcare system and
life-years gained. Resource use and costs were primarily
derived from diagnosis-related expenditure in a subset of
Belgian hospitals. Belgian life table data were obtained
and substituted for the Scottish data to account for differ-
ences in life expectancy.
RESULTS: The cost-effectiveness ratio remains well be-
low USD 25,000 (BEF 37  USD 1) per life-year gained,
the bound typically considered as “moderate to strong
evidence for adoption and appropriate utilization.”
CONCLUSION: Although the precise estimate depends
on the specifics of the country, the variation does not
have an impact on the treatment decision the initial study
supports.
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THERAPY: A PROSPECTIVE MULTICENTER 
COHORT STUDY
Willich SN, Völler H, Binting S, Gohlke H, Hahmann H, 
Kleber F, Klein G, Krobot K, Bestehorn K
The PIN Study Group, Institute for Social Medicine and 
Epidemiology, Charité University Hospital, Humboldt University 
of Berlin, Berlin, Germany
To determine the efficacy of cardiac inpatient rehabilita-
tion therapy (RT), 2442 consecutive patients (78% male,
age 60 (10 years), and 22% female, age 65 (10
years) in 18 rehabilitation centers were examined in the
period from January to June 1997. The primary indica-
tions for RT were myocardial infarction (56%), PTCA
(6%), and CABG (38%). RT was initiated 34 days (me-
dian) after the acute event. During hospitalization (26 
5 days), patients received standard health training and
medical therapy. Diagnostic tests and standardized sur-
veys were prospectively documented. The prevalence of
conventionally defined cardiovascular risk factors at the
start and end of the rehabilitation therapy is shown in the
table below.
